Evidence dossier · candidate cand-hpv-anaphylaxis · VICP program · · DRAFT — not a determination
This is a draft research-tracking dossier, not a determination that HPV vaccine causes Anaphylaxis, and not an incidence or legal finding. All evidence is flagged needs_human_review and must be reviewed before any page is published or cited. Every value is grounded in retrieved citations (PMID + retrieval date); unsourced items read "no evidence found / not assessable". Symmetric search: every supporting query has a mirror/null query, and zeros are shown (negative dossiers report the absence of signal).
Claim matrix (C1–C6, computed)
Claim
Label
Status
Missing nodes
C1
Coherent clinical object exists
insufficient_data
missing: A1 A2
C2
Consistent temporal window
insufficient_data
missing: A5
C3
Epidemiologic excess risk
supported
C4
Consistency / replication
supported
C5
Specificity (product / dose)
insufficient_data
missing: C2n
C6
Biological mechanism
insufficient_data
missing: E1
Two evidentiary bars apply to the epi nodes/claims (C3, C4): · VICP — preponderance of the evidence. · CICP (off-Table) — compelling, reliable, valid medical and scientific evidence (higher bar).
Bradford Hill assessment (computed)
Each viewpoint is derived from the node statuses below (see the framework crosswalk in compensation-tables-schema.md §8). Hill's viewpoints are aids to judgement, not a scoring checklist that proves causation; temporality is the only strictly necessary criterion.
Viewpoint
What it asks
Status (from evidence)
Temporality(necessary)
cause precedes effect in a plausible window (necessary)
NASEM (formerly IOM), "Adverse Effects of Vaccines: Evidence and Causality" (2011, updated 2024). Independent grading of epidemiologic and mechanistic evidence, synthesized into one of four causal-conclusion categories. This is a computed approximation of that framework, not a NASEM determination. See compensation-tables-schema.md §8bis.
Case-definition standard: Brighton Collaboration (named in spec §1: anaphylaxis) — governs the case-certainty scale on A1/A2/A6/A8 below. See compensation-tables-schema.md §8ter.
Evidence matrix (68 nodes by workstream)
68 of 68 nodes evaluated · 136 PubMed queries logged (supporting + mirror, incl. zeros). Statuses are computed from retrieved citations; not hand-set.
Definition & attribution 24/24 evaluated
A1 · Case reportsno_data
Measure: New definite object in risk window T Comparator: Pre-vaccination baseline Hit rule: Definite object present, onset in window, competing causes considered
Finding: no evidence found
Case-certainty distribution (Brighton Collaboration): 1 Level 3 (possible). Transparency layer — does not change this node's status or feed C1–C6.
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") case report OR case series Case reports pubmed · 66198 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") alternative diagnosis OR not vaccine-related pubmed · 4054 hits · run 2026-09-09
11 retrieved record(s)
ambiguous 33647971 · QJM : monthly journal of the Association (2021) — COVID-19 vaccine-related myositis.
does_not_resolve 37775180 · Clinical medicine (London, England) (2023) — SARS-CoV-2 vaccines and myocarditis.
ambiguous 30000765 · (2006) — Human Papillomavirus Vaccines.
ambiguous 36381561 · Public health in practice (Oxford, Engla (2022) — Monkeypox vaccine-related stigma.
does_not_resolve 36441403 · Current cardiology reports (2022) — COVID-19 Vaccine-Related Myocardial and Pericardial Inflammation.
ambiguous 32809680 · (2026) — Rubella Vaccine.
ambiguous 7114977 · Archives of internal medicine (1982) — Vaccine-related poliomyelitis.
A2 · Series with objective confirmationno_data
Measure: Definite object plus objective test Comparator: Reference range / diagnostic criteria Hit rule: Objective confirmation in >=1 case per the working definition
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") case report OR case series Series with objective confirmation pubmed · 5647 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") alternative diagnosis OR not vaccine-related pubmed · 4054 hits · run 2026-09-09
11 retrieved record(s)
ambiguous 33647971 · QJM : monthly journal of the Association (2021) — COVID-19 vaccine-related myositis.
does_not_resolve 37775180 · Clinical medicine (London, England) (2023) — SARS-CoV-2 vaccines and myocarditis.
ambiguous 30000765 · (2006) — Human Papillomavirus Vaccines.
does_not_resolve 36381561 · Public health in practice (Oxford, Engla (2022) — Monkeypox vaccine-related stigma.
does_not_resolve 36441403 · Current cardiology reports (2022) — COVID-19 Vaccine-Related Myocardial and Pericardial Inflammation.
ambiguous 32809680 · (2026) — Rubella Vaccine.
does_not_resolve 7114977 · Archives of internal medicine (1982) — Vaccine-related poliomyelitis.
A3 · Onset histogramno_data
Measure: Distribution of onset times after dose Comparator: Pre-specified risk window Hit rule: Onset clusters inside the pre-specified window (not uniform/flat)
Finding: No retrieved evidence addresses the onset distribution of anaphylaxis after HPV vaccination; the retrieved studies focus on COVID-19, monkeypox, rubella, polio vaccines, or general vaccine safety, and none concern HPV vaccine-related anaphylaxis.
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") case report OR case series Onset histogram pubmed · 3 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") alternative diagnosis OR not vaccine-related pubmed · 4054 hits · run 2026-09-09
11 retrieved record(s)
ambiguous 33647971 · QJM : monthly journal of the Association (2021) — COVID-19 vaccine-related myositis.
does_not_resolve 37775180 · Clinical medicine (London, England) (2023) — SARS-CoV-2 vaccines and myocarditis.
ambiguous 30000765 · (2006) — Human Papillomavirus Vaccines.
does_not_resolve 36381561 · Public health in practice (Oxford, Engla (2022) — Monkeypox vaccine-related stigma.
does_not_resolve 36441403 · Current cardiology reports (2022) — COVID-19 Vaccine-Related Myocardial and Pericardial Inflammation.
ambiguous 32809680 · (2026) — Rubella Vaccine.
does_not_resolve 7114977 · Archives of internal medicine (1982) — Vaccine-related poliomyelitis.
A4 · Temporal plausibilityno_data
Measure: Onset latency vs object pathophysiology Comparator: Object's known natural latency Hit rule: Onset latency consistent with the object's pathophysiology
Finding: No retrieved evidence addresses temporal plausibility of anaphylaxis following HPV vaccination; the only evidence retrieved concerns hepatitis B, COVID-19, and other vaccines, with no mention of HPV vaccine or anaphylaxis onset latency.
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") case report OR case series Temporal plausibility pubmed · 32 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") alternative diagnosis OR not vaccine-related pubmed · 4054 hits · run 2026-09-09
13 retrieved record(s)
ambiguous 15638050 · Clinical and experimental rheumatology (2004) — A case-series of adverse events, positive re-challenge of symptoms, and events in identical twins following hepatitis B vaccination: analysis of the Vaccine Adv
does_not_resolve 32294081 · PLoS neglected tropical diseases (2020) — Praziquantel and risk of visual disorders: Case series assessment.
ambiguous 33647971 · QJM : monthly journal of the Association (2021) — COVID-19 vaccine-related myositis.
does_not_resolve 37775180 · Clinical medicine (London, England) (2023) — SARS-CoV-2 vaccines and myocarditis.
ambiguous 30000765 · (2006) — Human Papillomavirus Vaccines.
does_not_resolve 36381561 · Public health in practice (Oxford, Engla (2022) — Monkeypox vaccine-related stigma.
does_not_resolve 36441403 · Current cardiology reports (2022) — COVID-19 Vaccine-Related Myocardial and Pericardial Inflammation.
A5 · Onset-interval documentationno_data
Measure: Onset interval documented in source Comparator: Dose date Hit rule: Onset interval is recorded (not imputed) in a primary source
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") case report OR case series Onset-interval documentation pubmed · 1 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") alternative diagnosis OR not vaccine-related pubmed · 4054 hits · run 2026-09-09
11 retrieved record(s)
ambiguous 33647971 · QJM : monthly journal of the Association (2021) — COVID-19 vaccine-related myositis.
does_not_resolve 37775180 · Clinical medicine (London, England) (2023) — SARS-CoV-2 vaccines and myocarditis.
ambiguous 30000765 · (2006) — Human Papillomavirus Vaccines.
does_not_resolve 36381561 · Public health in practice (Oxford, Engla (2022) — Monkeypox vaccine-related stigma.
does_not_resolve 36441403 · Current cardiology reports (2022) — COVID-19 Vaccine-Related Myocardial and Pericardial Inflammation.
ambiguous 32809680 · (2026) — Rubella Vaccine.
does_not_resolve 7114977 · Archives of internal medicine (1982) — Vaccine-related poliomyelitis.
A6 · Differential diagnosis excludedno_data
Measure: Competing causes assessed and excluded Comparator: Likely alternative diagnoses Hit rule: Pre-specified competing causes ruled out per the working definition
Finding: No evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") case report OR case series Differential diagnosis excluded pubmed · 428 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") alternative diagnosis OR not vaccine-related pubmed · 4054 hits · run 2026-09-09
11 retrieved record(s)
ambiguous 33647971 · QJM : monthly journal of the Association (2021) — COVID-19 vaccine-related myositis.
does_not_resolve 37775180 · Clinical medicine (London, England) (2023) — SARS-CoV-2 vaccines and myocarditis.
ambiguous 30000765 · (2006) — Human Papillomavirus Vaccines.
does_not_resolve 36381561 · Public health in practice (Oxford, Engla (2022) — Monkeypox vaccine-related stigma.
does_not_resolve 36441403 · Current cardiology reports (2022) — COVID-19 Vaccine-Related Myocardial and Pericardial Inflammation.
ambiguous 32809680 · (2026) — Rubella Vaccine.
ambiguous 7114977 · Archives of internal medicine (1982) — Vaccine-related poliomyelitis.
A7 · Rechallenge / re-exposureno_data
Measure: Object recurs on a further dose Comparator: First-dose response Hit rule: Object recurs after a subsequent dose (re-exposure)
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") case report OR case series Rechallenge / re-exposure pubmed · 3 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") alternative diagnosis OR not vaccine-related pubmed · 4054 hits · run 2026-09-09
11 retrieved record(s)
ambiguous 33647971 · QJM : monthly journal of the Association (2021) — COVID-19 vaccine-related myositis.
does_not_resolve 37775180 · Clinical medicine (London, England) (2023) — SARS-CoV-2 vaccines and myocarditis.
ambiguous 30000765 · (2006) — Human Papillomavirus Vaccines.
ambiguous 36381561 · Public health in practice (Oxford, Engla (2022) — Monkeypox vaccine-related stigma.
does_not_resolve 36441403 · Current cardiology reports (2022) — COVID-19 Vaccine-Related Myocardial and Pericardial Inflammation.
ambiguous 32809680 · (2026) — Rubella Vaccine.
ambiguous 7114977 · Archives of internal medicine (1982) — Vaccine-related poliomyelitis.
A8 · Adjudicated by criteria (Brighton Collaboration)no_data
Measure: Object adjudicated by published criteria Comparator: Published clinical / Brighton criteria Hit rule: Cases adjudicated to 'definite' by a published criterion set
Finding: No retrieved evidence addresses anaphylaxis adjudicated by published criteria after HPV vaccination. The single anaphylaxis case series (PMID 28390586) is from a pediatric ED and does not mention HPV vaccine or adjudicated criteria.
Case-certainty distribution (Brighton Collaboration): 1 Level 1 (definite). Transparency layer — does not change this node's status or feed C1–C6.
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") case report OR case series Adjudicated by criteria pubmed · 40 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") alternative diagnosis OR not vaccine-related pubmed · 4054 hits · run 2026-09-09
12 retrieved record(s)
does_not_resolve 28390586 · Annals of allergy, asthma & immunology : (2017) — An analysis of anaphylaxis cases at a single pediatric emergency department during a 1-year period.
does_not_resolve 33647971 · QJM : monthly journal of the Association (2021) — COVID-19 vaccine-related myositis.
does_not_resolve 37775180 · Clinical medicine (London, England) (2023) — SARS-CoV-2 vaccines and myocarditis.
ambiguous 30000765 · (2006) — Human Papillomavirus Vaccines.
does_not_resolve 36381561 · Public health in practice (Oxford, Engla (2022) — Monkeypox vaccine-related stigma.
does_not_resolve 36441403 · Current cardiology reports (2022) — COVID-19 Vaccine-Related Myocardial and Pericardial Inflammation.
ambiguous 32809680 · (2026) — Rubella Vaccine.
A9 · Natural-history consistencyno_data
Measure: Course matches the object's natural history Comparator: Known natural history of the object Hit rule: Clinical course (onset, peak, recovery) matches the object's natural history
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") case report OR case series Natural-history consistency pubmed · 104 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") alternative diagnosis OR not vaccine-related pubmed · 4054 hits · run 2026-09-09
11 retrieved record(s)
ambiguous 33647971 · QJM : monthly journal of the Association (2021) — COVID-19 vaccine-related myositis.
does_not_resolve 37775180 · Clinical medicine (London, England) (2023) — SARS-CoV-2 vaccines and myocarditis.
ambiguous 30000765 · (2006) — Human Papillomavirus Vaccines.
ambiguous 7114977 · Archives of internal medicine (1982) — Vaccine-related poliomyelitis.
A10 · No confounding objectno_data
Measure: Not attributable to a co-occurring condition Comparator: Co-occurring illness that could produce the object Hit rule: Object not better explained by a co-occurring condition (infection, etc.)
Finding: No retrieved evidence addresses HPV vaccine-related anaphylaxis. The retrieved articles cover COVID-19 vaccine myositis, myocarditis, cutaneous manifestations, clotting disorders, monkeypox vaccine stigma, rubella vaccine, polio vaccine, general vaccination adverse events, and HPV vaccine-related thyroid adverse events, but none report on anaphylaxis following HPV vaccination.
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") case report OR case series No confounding object pubmed · 20 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") alternative diagnosis OR not vaccine-related pubmed · 4054 hits · run 2026-09-09
11 retrieved record(s)
ambiguous 33647971 · QJM : monthly journal of the Association (2021) — COVID-19 vaccine-related myositis.
does_not_resolve 37775180 · Clinical medicine (London, England) (2023) — SARS-CoV-2 vaccines and myocarditis.
ambiguous 30000765 · (2006) — Human Papillomavirus Vaccines.
ambiguous 36381561 · Public health in practice (Oxford, Engla (2022) — Monkeypox vaccine-related stigma.
does_not_resolve 36441403 · Current cardiology reports (2022) — COVID-19 Vaccine-Related Myocardial and Pericardial Inflammation.
ambiguous 32809680 · (2026) — Rubella Vaccine.
ambiguous 7114977 · Archives of internal medicine (1982) — Vaccine-related poliomyelitis.
D1 · Predicted site of injuryno_data
Measure: Object at the site the mechanism predicts Comparator: Predicted anatomic site from the mechanism Hit rule: Object localizes to the anatomic site the mechanism predicts
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") anatomic localization Predicted site of injury mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Predicted site of injury not consistent with mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-09
D2 · Spared structuresno_data
Measure: Structures the mechanism should spare are spared Comparator: Structures predicted unaffected Hit rule: Structures predicted spared by the mechanism are indeed spared
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") anatomic localization Spared structures mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Spared structures not consistent with mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-09
D3 · Local vs systemic distributionno_data
Measure: Distribution matches mechanism scope Comparator: Local (injection site) vs systemic expectation Hit rule: Observed distribution (local vs systemic) matches the mechanism's predicted scope
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") anatomic localization Local vs systemic distribution mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Local vs systemic distribution not consistent with mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-09
D4 · Kinetics classno_data
Measure: Onset/offset kinetics match the mechanism Comparator: Expected kinetic class (acute vs chronic) Hit rule: Onset and offset kinetics are in the class the mechanism predicts
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") anatomic localization Kinetics class mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Kinetics class not consistent with mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-09
D5 · Platform-mechanism matchno_data
Measure: Mechanism is consistent with the platform Comparator: Mechanistic expectation for the platform Hit rule: The proposed mechanism is biologically consistent with the vaccine platform
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") anatomic localization Platform-mechanism match mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Platform-mechanism match not consistent with mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-09
H3 · Targeted treatment reversesno_data
Measure: A targeted treatment reverses the object in patients Comparator: Treatment-naive / placebo Hit rule: A mechanism-directed treatment reverses the object (vs control treatment)
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Targeted treatment reverses intervention OR treatment OR reversal pubmed · 15146614 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Targeted treatment reverses no effect intervention pubmed · 0 hits (0 hits — negative) · run 2026-09-09
I1 · No internal contradictionno_data
Measure: No node's finding contradicts another Comparator: Internal consistency across nodes Hit rule: No evaluated node directly contradicts another (coherence)
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") No internal contradiction coherence OR latency OR susceptibility pubmed · 870416 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") No internal contradiction inconsistent OR contradicts pubmed · 27618 hits · run 2026-09-09
1 retrieved record(s)
does_not_resolve 2699706 · Annali italiani di chirurgia (1989) — Etiology and risk factors of melanoma.
I2 · Analogy to a known objectno_data
Measure: Object analogous to a well-established analog Comparator: Established analog's profile Hit rule: The object's profile matches a well-established analog on key features
Finding: The retrieved evidence discusses measles vaccine efficacy thresholds and melanoma risk factors, with no mention of HPV vaccine or anaphylaxis.
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Analogy to a known object coherence OR latency OR susceptibility pubmed · 870416 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Analogy to a known object inconsistent OR contradicts pubmed · 27618 hits · run 2026-09-09
2 retrieved record(s)
does_not_resolve 8550283 · International journal of epidemiology (1995) — Minimum attack rate for measuring measles vaccine efficacy.
does_not_resolve 2699706 · Annali italiani di chirurgia (1989) — Etiology and risk factors of melanoma.
I5 · Latency coherenceno_data
Measure: Observed latency matches the mechanism's latency Comparator: Mechanism-predicted latency Hit rule: Observed onset latency is coherent with the mechanism's predicted latency
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Latency coherence coherence OR latency OR susceptibility pubmed · 870416 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Latency coherence inconsistent OR contradicts pubmed · 27618 hits · run 2026-09-09
2 retrieved record(s)
does_not_resolve 8550283 · International journal of epidemiology (1995) — Minimum attack rate for measuring measles vaccine efficacy.
does_not_resolve 2699706 · Annali italiani di chirurgia (1989) — Etiology and risk factors of melanoma.
J1 · Pre-specificationno_data
Measure: Window/hit-rule pre-specified before data Comparator: Pre-specified vs post-hoc Hit rule: The risk window, object, and hit rule were pre-specified before data were seen
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Pre-specification pre-specified OR adjudicated pubmed · 13562 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Pre-specification post-hoc OR hypothesis-generating only pubmed · 1719 hits · run 2026-09-09
2 retrieved record(s)
does_not_resolve 39226489 · Journal of clinical oncology : official (2024) — Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease
Measure: Contrary evidence is logged, not omitted Comparator: Support-only dossier Hit rule: Contrary / null / refuting findings are logged and shown alongside support
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Contrary-evidence log pre-specified OR adjudicated pubmed · 13562 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Contrary-evidence log post-hoc OR hypothesis-generating only pubmed · 1719 hits · run 2026-09-09
1 retrieved record(s)
does_not_resolve 39226489 · Journal of clinical oncology : official (2024) — Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease
J3 · No temporality-only claimno_data
Measure: Claim not based on temporality alone Comparator: Sequence-only evidence Hit rule: The claim is not supported by temporal sequence alone (independent evidence exists)
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") No temporality-only claim pre-specified OR adjudicated pubmed · 13562 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") No temporality-only claim post-hoc OR hypothesis-generating only pubmed · 1719 hits · run 2026-09-09
1 retrieved record(s)
does_not_resolve 39226489 · Journal of clinical oncology : official (2024) — Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease
J4 · Passive-surveillance roleno_data
Measure: Passive-surveillance findings bounded correctly Comparator: Active-surveillance confirmation Hit rule: Passive-surveillance signals are framed as hypothesis-generating, not confirmatory
Finding: No evidence found.
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Passive-surveillance role pre-specified OR adjudicated pubmed · 13562 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Passive-surveillance role post-hoc OR hypothesis-generating only pubmed · 1719 hits · run 2026-09-09
1 retrieved record(s)
does_not_resolve 39226489 · Journal of clinical oncology : official (2024) — Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease
J5 · Dose mappingno_data
Measure: Dose/lot exposure mapped to the object Comparator: Unmapped exposure Hit rule: Dose / lot exposure is mapped to the object where the mechanism predicts it
Finding: The retrieved evidence does not address HPV vaccine or anaphylaxis; it describes the use of large language models to identify immune-related adverse events from immune checkpoint inhibitors in cancer patients.
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Dose mapping pre-specified OR adjudicated pubmed · 13562 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Dose mapping post-hoc OR hypothesis-generating only pubmed · 1719 hits · run 2026-09-09
1 retrieved record(s)
does_not_resolve 39226489 · Journal of clinical oncology : official (2024) — Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease
Epidemiologic chassis 13/13 evaluated
B1 · Excess vs baselineno_data
Measure: RR/IRR vs unexposed or prior window Comparator: Unvaccinated person-time or pre-vaccination window Hit rule: RR/IRR > 1 with CI excluding 1 after pre-specified confounders
Finding: No retrieved evidence addresses the specific pair of HPV vaccine and anaphylaxis. One paper (PMID 34863620) compares anaphylaxis rates across vaccines including HPV vaccine, but it does not provide an RR/IRR estimate with a confidence interval excluding 1 after confounder adjustment for HPV vaccine specifically, nor does it use a self-controlled design or pre-specified risk window as required.
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Excess vs baseline incidence risk cohort OR self-controlled case series pubmed · 948 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") no association OR null OR no increased risk Excess vs baseline pubmed · 88514 hits · run 2026-09-09
does_not_resolve 37468475 · Nature communications (2023) — Herpes zoster vaccine safety in the Aotearoa New Zealand population: a self-controlled case series study.
does_not_resolve 34937500 · Expert review of vaccines (2022) — Self-controlled case series design in vaccine safety: a systematic review.
does_not_resolve 38875047 · The International journal of risk & safe (2024) — Self-controlled risk interval study of rotavirus vaccine safety: Findings and implications.
supports_node 40664645 · Nature communications (2025) — Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study.
does_not_resolve 24700656 · Clinical infectious diseases : an offici (2014) — Risk of stroke following herpes zoster: a self-controlled case-series study.
does_not_resolve 34672967 · Lancet (London, England) (2021) — Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, pha
does_not_resolve 34489307 · Gut (2022) — Non-alcoholic fatty liver disease and incident major adverse cardiovascular events: results from a nationwide histology cohort.
B2 · SCCSno_data
Measure: Self-controlled case series risk ratio Comparator: Individuals' own risk intervals (no-event) Hit rule: SCCS risk ratio > 1 in the post-vaccination window, CI excluding 1
Finding: No retrieved evidence addresses the association between HPV vaccine and anaphylaxis using a self-controlled case series design. The only SCCS study mentioning anaphylaxis evaluates COVID-19 mRNA vaccines, not HPV vaccine.
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") SCCS incidence risk cohort OR self-controlled case series pubmed · 948 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") no association OR null OR no increased risk SCCS pubmed · 88624 hits · run 2026-09-09
does_not_resolve 34937500 · Expert review of vaccines (2022) — Self-controlled case series design in vaccine safety: a systematic review.
does_not_resolve 38875047 · The International journal of risk & safe (2024) — Self-controlled risk interval study of rotavirus vaccine safety: Findings and implications.
supports_node 40664645 · Nature communications (2025) — Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study.
does_not_resolve 38388239 · Vaccine (2024) — Mortality risk after COVID-19 vaccination: A self-controlled case series study.
does_not_resolve 39795956 · International journal of molecular scien (2024) — The Potential Metalloestrogenic Effect of Aluminum on Breast Cancer Risk for Antiperspirant Users.
does_not_resolve 37176704 · Journal of clinical medicine (2023) — Oral Cavity Squamous Cell Carcinoma Risk Factors: State of the Art.
does_not_resolve 28468712 · Deutsches Arzteblatt international (2017) — Risk of Intussusception After Rotavirus Vaccination.
B3 · Cohort / risk-intervalno_data
Measure: Incidence rate ratio in defined window Comparator: Pre-specified risk vs comparison interval Hit rule: IRR > 1 in the pre-specified window, CI excluding 1, stratified by age/sex
Finding: No retrieved evidence addresses the specific pair of HPV vaccine and anaphylaxis using a cohort or risk-interval design with IRR > 1, CI excluding 1, stratified by age/sex.
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Cohort / risk-interval incidence risk cohort OR self-controlled case series pubmed · 948 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") no association OR null OR no increased risk Cohort / risk-interval pubmed · 88123 hits · run 2026-09-09
does_not_resolve 34937500 · Expert review of vaccines (2022) — Self-controlled case series design in vaccine safety: a systematic review.
does_not_resolve 38875047 · The International journal of risk & safe (2024) — Self-controlled risk interval study of rotavirus vaccine safety: Findings and implications.
supports_node 40664645 · Nature communications (2025) — Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study.
does_not_resolve 38388239 · Vaccine (2024) — Mortality risk after COVID-19 vaccination: A self-controlled case series study.
does_not_resolve 23884605 · Tumour biology : the journal of the Inte (2013) — Association between glutathione S-transferase M 1 null genotype and risk of ovarian cancer: a meta-analysis.
does_not_resolve 41284649 · PloS one (2025) — Risk of neurologic or immune-mediated adverse events after COVID-19 diagnosis in the United States.
B4 · Meta-analysis / poolingno_data
Measure: Pooled effect across studies Comparator: Pooled estimate with heterogeneity Hit rule: Pooled estimate > 1 (or < 1) with quantified heterogeneity (I2)
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Meta-analysis / pooling incidence risk cohort OR self-controlled case series pubmed · 948 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") no association OR null OR no increased risk Meta-analysis / pooling pubmed · 111981 hits · run 2026-09-09
does_not_resolve 37468475 · Nature communications (2023) — Herpes zoster vaccine safety in the Aotearoa New Zealand population: a self-controlled case series study.
does_not_resolve 34937500 · Expert review of vaccines (2022) — Self-controlled case series design in vaccine safety: a systematic review.
does_not_resolve 38875047 · The International journal of risk & safe (2024) — Self-controlled risk interval study of rotavirus vaccine safety: Findings and implications.
supports_node 40664645 · Nature communications (2025) — Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study.
does_not_resolve 24700656 · Clinical infectious diseases : an offici (2014) — Risk of stroke following herpes zoster: a self-controlled case-series study.
does_not_resolve 29402646 · Journal of the American Medical Director (2018) — Fall-Risk-Increasing Drugs: A Systematic Review and Meta-analysis: III. Others.
does_not_resolve 41286768 · BMC public health (2025) — Prevalence and risk factors of hepatitis B and C among prison inmates in Nigeria: a systematic review and meta-analysis.
B5 · Negative-control outcomesno_data
Measure: No excess for outcomes the vaccine should not cause Comparator: Negative-control outcomes (unaffected by mechanism) Hit rule: Null for negative-control outcomes while target outcome is positive (specificity)
Finding: The retrieved evidence includes a study that reports anaphylaxis rates for various vaccines, ranking human papillomavirus (HPV) vaccine below several others in terms of reported anaphylaxis rate (PMID 34863620), but this study does not assess whether HPV vaccine causes a new excess of anaphylaxis in a self-controlled design with a defined risk window. No retrieved study directly examines the HPV vaccine and anaphylaxis as a negative-control outcome with a null hypothesis.
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Negative-control outcomes incidence risk cohort OR self-controlled case series pubmed · 948 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") no association OR null OR no increased risk Negative-control outcomes pubmed · 88325 hits · run 2026-09-09
does_not_resolve 37468475 · Nature communications (2023) — Herpes zoster vaccine safety in the Aotearoa New Zealand population: a self-controlled case series study.
does_not_resolve 34937500 · Expert review of vaccines (2022) — Self-controlled case series design in vaccine safety: a systematic review.
does_not_resolve 38875047 · The International journal of risk & safe (2024) — Self-controlled risk interval study of rotavirus vaccine safety: Findings and implications.
supports_node 40664645 · Nature communications (2025) — Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study.
does_not_resolve 24700656 · Clinical infectious diseases : an offici (2014) — Risk of stroke following herpes zoster: a self-controlled case-series study.
does_not_resolve 38833248 · JAMA network open (2024) — Valproate Use During Spermatogenesis and Risk to Offspring.
does_not_resolve 34863620 · Vaccine (2022) — Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines.
B6 · Other-antigen comparisonno_data
Measure: Risk vs a different-antigen comparator Comparator: Comparator product with a different antigen Hit rule: Risk specific to the target antigen, not shared with the comparator antigen
Finding: The retrieved evidence does not address the specific comparison of anaphylaxis risk following HPV vaccine versus a different-antigen comparator; only a general anaphylaxis rate for HPV vaccine is mentioned in a ranking context, with no comparator antigen analysis.
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Other-antigen comparison incidence risk cohort OR self-controlled case series pubmed · 948 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") no association OR null OR no increased risk Other-antigen comparison pubmed · 88087 hits · run 2026-09-09
does_not_resolve 37468475 · Nature communications (2023) — Herpes zoster vaccine safety in the Aotearoa New Zealand population: a self-controlled case series study.
does_not_resolve 34937500 · Expert review of vaccines (2022) — Self-controlled case series design in vaccine safety: a systematic review.
does_not_resolve 38875047 · The International journal of risk & safe (2024) — Self-controlled risk interval study of rotavirus vaccine safety: Findings and implications.
supports_node 40664645 · Nature communications (2025) — Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study.
does_not_resolve 24700656 · Clinical infectious diseases : an offici (2014) — Risk of stroke following herpes zoster: a self-controlled case-series study.
does_not_resolve 23884605 · Tumour biology : the journal of the Inte (2013) — Association between glutathione S-transferase M 1 null genotype and risk of ovarian cancer: a meta-analysis.
does_not_resolve 34863620 · Vaccine (2022) — Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines.
B7 · Absolute riskno_data
Measure: Per-100k risk in window Comparator: Absolute incidence per 100k Hit rule: Absolute risk reported and stable across the window (not an artifact of rarity)
Finding: No retrieved evidence reports absolute risk of anaphylaxis per 100,000 doses following HPV vaccination; the retrieved studies focus on shingles, zoster, rotavirus, COVID-19 mRNA vaccines, hormonal contraception, radiotherapy, omega-6/omega-3 ratios, and idiopathic pulmonary fibrosis, with no mention of HPV vaccine or anaphylaxis.
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Absolute risk incidence risk cohort OR self-controlled case series pubmed · 948 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") no association OR null OR no increased risk Absolute risk pubmed · 111381 hits · run 2026-09-09
refutes_node 37468475 · Nature communications (2023) — Herpes zoster vaccine safety in the Aotearoa New Zealand population: a self-controlled case series study.
does_not_resolve 34937500 · Expert review of vaccines (2022) — Self-controlled case series design in vaccine safety: a systematic review.
does_not_resolve 38875047 · The International journal of risk & safe (2024) — Self-controlled risk interval study of rotavirus vaccine safety: Findings and implications.
ambiguous 40664645 · Nature communications (2025) — Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study.
does_not_resolve 24700656 · Clinical infectious diseases : an offici (2014) — Risk of stroke following herpes zoster: a self-controlled case-series study.
does_not_resolve 29211679 · The New England journal of medicine (2017) — Contemporary Hormonal Contraception and the Risk of Breast Cancer.
does_not_resolve 23484825 · The New England journal of medicine (2013) — Risk of ischemic heart disease in women after radiotherapy for breast cancer.
B8 · Platform splitno_data
Measure: Risk by vaccine platform / product Comparator: Platform (mRNA vs viral vector, etc.) Hit rule: Risk attributable to a specific platform, not to 'a vaccine' generally
Finding: The retrieved evidence includes a study showing that anaphylaxis rates for COVID-19 vaccines rank behind those for HPV vaccines (PMID 34863620), and an overview of quadrivalent HPV vaccine safety (PMID 26107345) that does not specifically address anaphylaxis risk by vaccine platform. No retrieved studies provide a platform-specific risk estimate for anaphylaxis after HPV vaccination that isolates a particular vaccine platform effect versus the general vaccine class.
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Platform split incidence risk cohort OR self-controlled case series pubmed · 948 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") no association OR null OR no increased risk Platform split pubmed · 88152 hits · run 2026-09-09
does_not_resolve 34937500 · Expert review of vaccines (2022) — Self-controlled case series design in vaccine safety: a systematic review.
does_not_resolve 38875047 · The International journal of risk & safe (2024) — Self-controlled risk interval study of rotavirus vaccine safety: Findings and implications.
supports_node 40664645 · Nature communications (2025) — Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study.
does_not_resolve 38388239 · Vaccine (2024) — Mortality risk after COVID-19 vaccination: A self-controlled case series study.
does_not_resolve 34863620 · Vaccine (2022) — Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines.
does_not_resolve 26107345 · The Pediatric infectious disease journal (2015) — An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015.
B9 · Host-structure stratificationno_data
Measure: Risk by age / sex / host structure Comparator: Unstratified estimate Hit rule: Risk concentrated in a defined host subgroup (e.g. young males), stable across sources
Finding: The retrieved evidence includes one study (PMID 40664645) that mentions anaphylaxis as a monitored adverse event following XBB.1.5-containing COVID-19 mRNA vaccines, but no retrieved study addresses risk of anaphylaxis stratified by age, sex, or host subgroup for the HPV vaccine. No evidence supports risk concentration in a defined host subgroup for HPV vaccine anaphylaxis.
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Host-structure stratification incidence risk cohort OR self-controlled case series pubmed · 948 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") no association OR null OR no increased risk Host-structure stratification pubmed · 88085 hits · run 2026-09-09
does_not_resolve 37468475 · Nature communications (2023) — Herpes zoster vaccine safety in the Aotearoa New Zealand population: a self-controlled case series study.
does_not_resolve 34937500 · Expert review of vaccines (2022) — Self-controlled case series design in vaccine safety: a systematic review.
does_not_resolve 38875047 · The International journal of risk & safe (2024) — Self-controlled risk interval study of rotavirus vaccine safety: Findings and implications.
supports_node 40664645 · Nature communications (2025) — Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study.
does_not_resolve 24700656 · Clinical infectious diseases : an offici (2014) — Risk of stroke following herpes zoster: a self-controlled case-series study.
does_not_resolve 34863620 · Vaccine (2022) — Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines.
does_not_resolve 23884605 · Tumour biology : the journal of the Inte (2013) — Association between glutathione S-transferase M 1 null genotype and risk of ovarian cancer: a meta-analysis.
B10 · Formulation / component changeno_data
Measure: Risk tracks a formulation change Comparator: Pre- vs post-change formulation Hit rule: Risk change tracks a documented formulation / component change over time
Finding: No evidence found that directly addresses the relationship between anaphylaxis attributed to HPV vaccine and a documented formulation or component change over time.
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Formulation / component change incidence risk cohort OR self-controlled case series pubmed · 948 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") no association OR null OR no increased risk Formulation / component change pubmed · 88247 hits · run 2026-09-09
does_not_resolve 37468475 · Nature communications (2023) — Herpes zoster vaccine safety in the Aotearoa New Zealand population: a self-controlled case series study.
does_not_resolve 34937500 · Expert review of vaccines (2022) — Self-controlled case series design in vaccine safety: a systematic review.
does_not_resolve 38875047 · The International journal of risk & safe (2024) — Self-controlled risk interval study of rotavirus vaccine safety: Findings and implications.
supports_node 40664645 · Nature communications (2025) — Evaluating the safety of XBB.1.5-containing COVID-19 mRNA vaccines using a self-controlled case series study.
does_not_resolve 24700656 · Clinical infectious diseases : an offici (2014) — Risk of stroke following herpes zoster: a self-controlled case-series study.
does_not_resolve 41092926 · Lancet (London, England) (2025) — Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 su
does_not_resolve 34863620 · Vaccine (2022) — Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines.
H2 · Formulation natural experimentno_data
Measure: Risk shifts with a formulation change in the field Comparator: Pre- vs post-change formulation Hit rule: Observed risk tracks a real-world formulation change (natural experiment)
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Formulation natural experiment intervention OR treatment OR reversal pubmed · 15146614 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Formulation natural experiment no effect intervention pubmed · 0 hits (0 hits — negative) · run 2026-09-09
1 retrieved record(s)
does_not_resolve 26937198 · Vascular health and risk management (2016) — Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab.
H4 · Policy / pause signalno_data
Measure: Risk signal appears/disappears across a pause or policy change Comparator: Pre- vs post-pause period Hit rule: The signal appears or disappears coherently with a rollout / pause (H4)
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Policy / pause signal intervention OR treatment OR reversal pubmed · 15146614 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Policy / pause signal no effect intervention pubmed · 0 hits (0 hits — negative) · run 2026-09-09
1 retrieved record(s)
does_not_resolve 38189107 · Expert review of vaccines (2024) — Neoadjuvant personalized cancer vaccines: the final frontier?
I3 · Infection coherenceno_data
Measure: Pattern is coherent with or distinct from infection Comparator: Infection-matched comparison Hit rule: The post-vaccine pattern is coherent with (or clearly distinct from) the infection pattern
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Infection coherence coherence OR latency OR susceptibility pubmed · 870416 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Infection coherence inconsistent OR contradicts pubmed · 27618 hits · run 2026-09-09
2 retrieved record(s)
does_not_resolve 8550283 · International journal of epidemiology (1995) — Minimum attack rate for measuring measles vaccine efficacy.
does_not_resolve 2699706 · Annali italiani di chirurgia (1989) — Etiology and risk factors of melanoma.
Mediator & biological gradient 24/24 evaluated
C1n · Dose strength gradientno_data
Measure: Risk vs dose strength (dose size) Comparator: Lower dose strength Hit rule: Monotonic dose-response in dose strength (larger dose -> higher risk)
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Dose strength gradient dose-response OR dose effect pubmed · 1299586 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") no dose effect OR no dose-response Dose strength gradient pubmed · 117 hits · run 2026-09-09
3 retrieved record(s)
does_not_resolve 39082700 · The Journal of infectious diseases (2025) — Effectiveness of MenB-4C Vaccine Against Gonorrhea: A Systematic Review and Meta-analysis.
does_not_resolve 23637071 · Drug safety (2013) — Safety of human papillomavirus vaccines: a review.
refutes_node 31740498 · Pediatrics (2019) — Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine.
C2n · Dose number gradientno_data
Measure: Risk vs dose number (1st vs 2nd vs 3rd) Comparator: First dose Hit rule: Risk increases (or shows a defined pattern) with dose number
Finding: No retrieved evidence addresses the relationship between HPV vaccine dose number and anaphylaxis risk; the two retrieved studies concern MenB-4C vaccine against gonorrhea and an inactivated Crimean-Congo hemorrhagic fever vaccine, respectively.
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Dose number gradient dose-response OR dose effect pubmed · 1299586 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") no dose effect OR no dose-response Dose number gradient pubmed · 562 hits · run 2026-09-09
2 retrieved record(s)
does_not_resolve 39082700 · The Journal of infectious diseases (2025) — Effectiveness of MenB-4C Vaccine Against Gonorrhea: A Systematic Review and Meta-analysis.
does_not_resolve 34703927 · Heliyon (2021) — Development of a protective inactivated vaccine against Crimean-Congo hemorrhagic fever infection.
C3n · Measured-exposure tertilesno_data
Measure: Risk vs measured exposure tertile Comparator: Lowest-exposure tertile Hit rule: Risk ordered by measured-exposure tertile (high > mid > low)
Finding: The retrieved evidence includes near real-time surveillance that prespecified anaphylaxis as an outcome following 9-valent HPV vaccine (PMID 31740498), and mentions of anaphylaxis or hypersensitivity in Australian AEFI surveillance (PMID 27295585, 19050332, 19374268), but none of these studies report measured-exposure tertiles of HPV vaccine dose or assess risk ordered by tertile of exposure.
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Measured-exposure tertiles dose-response OR dose effect pubmed · 1299586 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") no dose effect OR no dose-response Measured-exposure tertiles pubmed · 6 hits · run 2026-09-09
6 retrieved record(s)
does_not_resolve 39082700 · The Journal of infectious diseases (2025) — Effectiveness of MenB-4C Vaccine Against Gonorrhea: A Systematic Review and Meta-analysis.
does_not_resolve 23637071 · Drug safety (2013) — Safety of human papillomavirus vaccines: a review.
refutes_node 31740498 · Pediatrics (2019) — Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine.
supports_node 27295585 · Human vaccines & immunotherapeutics (2016) — Adverse events following HPV immunization in Australia: Establishment of a clinical network.
ambiguous 19050332 · BMJ (Clinical research ed.) (2008) — Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study.
supports_node 19374268 · Communicable diseases intelligence quart (2008) — Annual report: surveillance of adverse events following immunisation in Australia, 2007.
C4n · Organoid concentration curveno_data
Measure: Effect vs antigen concentration in organoid Comparator: Vehicle / zero antigen Hit rule: Dose-dependent effect across a graded concentration curve
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Organoid concentration curve dose-response OR dose effect pubmed · 1299586 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") no dose effect OR no dose-response Organoid concentration curve pubmed · 17 hits · run 2026-09-09
6 retrieved record(s)
does_not_resolve 39082700 · The Journal of infectious diseases (2025) — Effectiveness of MenB-4C Vaccine Against Gonorrhea: A Systematic Review and Meta-analysis.
supports_node 23637071 · Drug safety (2013) — Safety of human papillomavirus vaccines: a review.
does_not_resolve 31740498 · Pediatrics (2019) — Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine.
supports_node 27295585 · Human vaccines & immunotherapeutics (2016) — Adverse events following HPV immunization in Australia: Establishment of a clinical network.
supports_node 19050332 · BMJ (Clinical research ed.) (2008) — Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study.
supports_node 19374268 · Communicable diseases intelligence quart (2008) — Annual report: surveillance of adverse events following immunisation in Australia, 2007.
C5n · EC50 vs Cmax coherenceno_data
Measure: Measured exposure reaches effect threshold Comparator: Pharmacokinetic Cmax vs EC50 Hit rule: Achieved exposure (Cmax/tissue) plausibly reaches the in-vitro EC50
Finding: No retrieved evidence directly assesses whether measured exposure (Cmax/tissue) to HPV vaccine plausibly reaches the in-vitro EC50 for anaphylaxis; the available studies discuss hypersensitivity reactions to HPV vaccine in clinical case series and surveillance, but do not report pharmacokinetic or pharmacodynamic data linking exposure concentrations to EC50.
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") EC50 vs Cmax coherence dose-response OR dose effect pubmed · 1299586 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") no dose effect OR no dose-response EC50 vs Cmax coherence pubmed · 6 hits · run 2026-09-09
6 retrieved record(s)
does_not_resolve 39082700 · The Journal of infectious diseases (2025) — Effectiveness of MenB-4C Vaccine Against Gonorrhea: A Systematic Review and Meta-analysis.
ambiguous 23637071 · Drug safety (2013) — Safety of human papillomavirus vaccines: a review.
refutes_node 31740498 · Pediatrics (2019) — Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine.
supports_node 27295585 · Human vaccines & immunotherapeutics (2016) — Adverse events following HPV immunization in Australia: Establishment of a clinical network.
supports_node 19050332 · BMJ (Clinical research ed.) (2008) — Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study.
supports_node 19374268 · Communicable diseases intelligence quart (2008) — Annual report: surveillance of adverse events following immunisation in Australia, 2007.
E1 · Mediator identified in casesno_data
Measure: Mediator present in affected tissue/cells Comparator: Unaffected tissue / control Hit rule: The hypothesized mediator is detected in the affected compartment and not (or less) in control
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") mechanism Mediator identified in cases in vitro OR patient-derived pubmed · 29266 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Mediator identified in cases not associated mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-09
E2 · Mediator in healthy vaccineesno_data
Measure: Mediator detectable after vaccination Comparator: Pre-vaccination baseline Hit rule: Mediator appears after vaccination and tracks the exposure window
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") mechanism Mediator in healthy vaccinees in vitro OR patient-derived pubmed · 29266 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Mediator in healthy vaccinees not associated mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-09
E3 · Infection contrastno_data
Measure: Mediator absent/low after natural infection Comparator: Recovered natural infection Hit rule: Mediator signal is specific to vaccination vs a comparable natural-infection control
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") mechanism Infection contrast in vitro OR patient-derived pubmed · 29266 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Infection contrast not associated mechanism pubmed · 1 hits · run 2026-09-09
1 retrieved record(s)
does_not_resolve 41713327 · Vaccine (2026) — What is the impact of the safety signal on dengue vaccination coverage among adolescents in Brazil?
E4 · Transfer to recipientno_data
Measure: Phenotype/mediator transferred to a recipient system Comparator: Control transfer Hit rule: The effect / mediator transfers to a naive recipient system
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") mechanism Transfer to recipient in vitro OR patient-derived pubmed · 29266 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Transfer to recipient not associated mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-09
E5 · Transfer specificityno_data
Measure: Transfer requires the specific mediator Comparator: Transfer with mediator present Hit rule: Transfer effect is lost when the specific mediator is removed
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") mechanism Transfer specificity in vitro OR patient-derived pubmed · 29266 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Transfer specificity not associated mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-09
E6 · Depletion / knockdownno_data
Measure: Removing the mediator reduces the effect Comparator: Non-targeted knockdown Hit rule: Knockdown / depletion of the mediator reduces the phenotype
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") mechanism Depletion / knockdown in vitro OR patient-derived pubmed · 29266 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Depletion / knockdown not associated mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-09
E7 · Add-back rescueno_data
Measure: Adding the mediator restores the effect Comparator: Add-back of a control protein Hit rule: Adding back the mediator (not a control) restores the phenotype
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") mechanism Add-back rescue in vitro OR patient-derived pubmed · 29266 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Add-back rescue not associated mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-09
E8 · Neutralizationno_data
Measure: Neutralizing the mediator blocks the effect Comparator: Isotype control Hit rule: Neutralization of the mediator (not an isotype control) blocks the phenotype
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") mechanism Neutralization in vitro OR patient-derived pubmed · 29266 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Neutralization not associated mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-09
E9 · Isotype controlno_data
Measure: Isotype control does not reproduce the effect Comparator: Active antibody Hit rule: An isotype control fails to reproduce the block/activation
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") mechanism Isotype control in vitro OR patient-derived pubmed · 29266 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Isotype control not associated mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-09
F1 · Full product reproducesno_data
Measure: Full vaccine product reproduces the effect Comparator: No-product control Hit rule: The full product (not a subcomponent) reproduces the effect
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Full product reproduces component OR antigen OR vector pubmed · 2045722 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Full product reproduces no effect component isolation pubmed · 0 hits (0 hits — negative) · run 2026-09-09
does_not_resolve 15174971 · Expert opinion on biological therapy (2004) — Particle-mediated DNA vaccine delivery to the skin.
does_not_resolve 29550258 · Immunology letters (2018) — Live bacterial vaccine vector and delivery strategies of heterologous antigen: A review.
does_not_resolve 25876176 · Human vaccines & immunotherapeutics (2015) — Progress on adenovirus-vectored universal influenza vaccines.
does_not_resolve 25142448 · Current gene therapy (2014) — Improving DNA vaccine performance through vector design.
does_not_resolve 27384578 · Viruses (2016) — Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines.
F2 · Empty vector / particleno_data
Measure: Vector/particle without antigen reproduces (or not) Comparator: Full product Hit rule: Effect attributed to (or excluded from) the vector/particle backbone alone
Finding: The retrieved evidence discusses virus-vectored influenza vaccines, live bacterial vaccine vectors, measles vaccine, adenovirus-vectored influenza vaccines, lentiviral vector rabies vaccines, and viral vector-based cancer vaccines, but none of the abstracts mention HPV vaccine, anaphylaxis, or any adverse event related to vaccine vectors or particles in the context of anaphylaxis.
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Empty vector / particle component OR antigen OR vector pubmed · 2045722 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Empty vector / particle no effect component isolation pubmed · 0 hits (0 hits — negative) · run 2026-09-09
does_not_resolve 25876176 · Human vaccines & immunotherapeutics (2015) — Progress on adenovirus-vectored universal influenza vaccines.
does_not_resolve 40857335 · PLoS neglected tropical diseases (2025) — Novel rabies vaccine candidates development based on pseudotyped lentiviral vectors with rabies virus glycoprotein.
does_not_resolve 21952287 · Cancer journal (Sudbury, Mass.) (2011) — Viral vector-based therapeutic cancer vaccines.
F3 · Antigen alone reproducesno_data
Measure: Isolated antigen reproduces the effect Comparator: Vehicle Hit rule: The isolated antigen (not the full product) reproduces the effect
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Antigen alone reproduces component OR antigen OR vector pubmed · 2045722 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Antigen alone reproduces no effect component isolation pubmed · 0 hits (0 hits — negative) · run 2026-09-09
does_not_resolve 25876176 · Human vaccines & immunotherapeutics (2015) — Progress on adenovirus-vectored universal influenza vaccines.
does_not_resolve 40857335 · PLoS neglected tropical diseases (2025) — Novel rabies vaccine candidates development based on pseudotyped lentiviral vectors with rabies virus glycoprotein.
does_not_resolve 21952287 · Cancer journal (Sudbury, Mass.) (2011) — Viral vector-based therapeutic cancer vaccines.
F4 · Irrelevant cargono_data
Measure: Irrelevant cargo does not reproduce the effect Comparator: Vector with the target antigen Hit rule: Irrelevant cargo fails to reproduce the effect (specificity)
Finding: No evidence found. The retrieved literature discusses viral and bacterial vaccine vectors for influenza, measles, rabies, and cancer, but none address HPV vaccine, anaphylaxis, or the specific irreproducibility of anaphylaxis by irrelevant cargo.
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Irrelevant cargo component OR antigen OR vector pubmed · 2045722 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Irrelevant cargo no effect component isolation pubmed · 0 hits (0 hits — negative) · run 2026-09-09
does_not_resolve 25876176 · Human vaccines & immunotherapeutics (2015) — Progress on adenovirus-vectored universal influenza vaccines.
does_not_resolve 40857335 · PLoS neglected tropical diseases (2025) — Novel rabies vaccine candidates development based on pseudotyped lentiviral vectors with rabies virus glycoprotein.
does_not_resolve 21952287 · Cancer journal (Sudbury, Mass.) (2011) — Viral vector-based therapeutic cancer vaccines.
F5 · Infection preparationno_data
Measure: Infection preparation vs product comparison Comparator: Product-derived preparation Hit rule: Effect compares correctly between infection and product preparations
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Infection preparation component OR antigen OR vector pubmed · 2045722 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Infection preparation no effect component isolation pubmed · 0 hits (0 hits — negative) · run 2026-09-09
does_not_resolve 25876176 · Human vaccines & immunotherapeutics (2015) — Progress on adenovirus-vectored universal influenza vaccines.
does_not_resolve 40857335 · PLoS neglected tropical diseases (2025) — Novel rabies vaccine candidates development based on pseudotyped lentiviral vectors with rabies virus glycoprotein.
does_not_resolve 21952287 · Cancer journal (Sudbury, Mass.) (2011) — Viral vector-based therapeutic cancer vaccines.
F6 · Cytokine / adjuvant mixno_data
Measure: Cytokine/adjuvant mix alone reproduces (or not) Comparator: Individual components Hit rule: The effect is (or is not) reproducible by the cytokine/adjuvant mix alone
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Cytokine / adjuvant mix component OR antigen OR vector pubmed · 2045722 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Cytokine / adjuvant mix no effect component isolation pubmed · 0 hits (0 hits — negative) · run 2026-09-09
does_not_resolve 25876176 · Human vaccines & immunotherapeutics (2015) — Progress on adenovirus-vectored universal influenza vaccines.
does_not_resolve 40857335 · PLoS neglected tropical diseases (2025) — Novel rabies vaccine candidates development based on pseudotyped lentiviral vectors with rabies virus glycoprotein.
does_not_resolve 21952287 · Cancer journal (Sudbury, Mass.) (2011) — Viral vector-based therapeutic cancer vaccines.
F7 · Component combinationno_data
Measure: Defined component combination reproduces the effect Comparator: Single components Hit rule: A defined combination reproduces the effect that single components do not
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Component combination component OR antigen OR vector pubmed · 2045722 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Component combination no effect component isolation pubmed · 0 hits (0 hits — negative) · run 2026-09-09
does_not_resolve 15174971 · Expert opinion on biological therapy (2004) — Particle-mediated DNA vaccine delivery to the skin.
does_not_resolve 29550258 · Immunology letters (2018) — Live bacterial vaccine vector and delivery strategies of heterologous antigen: A review.
does_not_resolve 25876176 · Human vaccines & immunotherapeutics (2015) — Progress on adenovirus-vectored universal influenza vaccines.
does_not_resolve 25142448 · Current gene therapy (2014) — Improving DNA vaccine performance through vector design.
does_not_resolve 27384578 · Viruses (2016) — Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines.
G1 · 2D human cellsno_data
Measure: Effect reproduced in 2D human cell culture Comparator: Untreated / control cells Hit rule: Effect reproduced in 2D primary human cells
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") 2D human cells animal OR organoid OR cell model pubmed · 1819354 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") 2D human cells not reproduced model pubmed · 0 hits (0 hits — negative) · run 2026-09-09
G2 · Organoid / chipno_data
Measure: Effect reproduced in organoid / organ-on-chip Comparator: Unexposed organoid Hit rule: Effect reproduced in a 3D organoid / organ-on-chip system
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Organoid / chip animal OR organoid OR cell model pubmed · 1819354 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Organoid / chip not reproduced model pubmed · 0 hits (0 hits — negative) · run 2026-09-09
H1 · Block in vitro / in vivono_data
Measure: Blocking the mediator/mechanism prevents the effect Comparator: Control intervention Hit rule: Blocking the mechanism prevents or reverses the effect (not with a control intervention)
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Block in vitro / in vivo intervention OR treatment OR reversal pubmed · 15146614 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Block in vitro / in vivo no effect intervention pubmed · 0 hits (0 hits — negative) · run 2026-09-09
1 retrieved record(s)
does_not_resolve 38189107 · Expert review of vaccines (2024) — Neoadjuvant personalized cancer vaccines: the final frontier?
Clinical / animal / host 7/7 evaluated
E10 · Host-line dependenceno_data
Measure: Effect depends on host line/cell type Comparator: Susceptible host line Hit rule: Effect is restricted to a defined host line / genotype, not universal
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") mechanism Host-line dependence in vitro OR patient-derived pubmed · 29266 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Host-line dependence not associated mechanism pubmed · 0 hits (0 hits — negative) · run 2026-09-09
G3 · Animal, clinical routeno_data
Measure: Effect in animal via the clinical route of administration Comparator: Vehicle, same route Hit rule: Effect reproduced in an animal using the clinical route of administration
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Animal, clinical route animal OR organoid OR cell model pubmed · 1819354 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Animal, clinical route not reproduced model pubmed · 0 hits (0 hits — negative) · run 2026-09-09
G4 · Susceptible animalno_data
Measure: Effect in a susceptible animal model Comparator: Non-susceptible model Hit rule: Effect in a defined susceptible animal model
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Susceptible animal animal OR organoid OR cell model pubmed · 1819354 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Susceptible animal not reproduced model pubmed · 0 hits (0 hits — negative) · run 2026-09-09
G5 · Replication across labsno_data
Measure: Effect replicated in an independent lab Comparator: Original result Hit rule: The key effect is replicated in an independent laboratory
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Replication across labs animal OR organoid OR cell model pubmed · 1819354 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Replication across labs not reproduced model pubmed · 0 hits (0 hits — negative) · run 2026-09-09
G6 · Blinded scoringno_data
Measure: Outcomes scored blinded Comparator: Unblinded reference Hit rule: Primary outcomes scored by a blinded assessor
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Blinded scoring animal OR organoid OR cell model pubmed · 1819354 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Blinded scoring not reproduced model pubmed · 0 hits (0 hits — negative) · run 2026-09-09
G7 · Experimental time courseno_data
Measure: Effect follows a defined experimental time course Comparator: No-exposure time course Hit rule: The effect's onset/offset follows a defined experimental time course
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Experimental time course animal OR organoid OR cell model pubmed · 1819354 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Experimental time course not reproduced model pubmed · 0 hits (0 hits — negative) · run 2026-09-09
I4 · Susceptibility traitno_data
Measure: A host trait / marker defines susceptibility Comparator: Trait-negative hosts Hit rule: A defined host trait / marker enriches for susceptibility
Finding: no evidence found
Cited: (none)
supporting: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Susceptibility trait coherence OR latency OR susceptibility pubmed · 870416 hits · run 2026-09-09
mirror: HPV vaccine (anaphylaxis OR "anaphylactic" OR "severe allergic reaction") Susceptibility trait inconsistent OR contradicts pubmed · 27618 hits · run 2026-09-09
1 retrieved record(s)
does_not_resolve 15578364 · Clinical infectious diseases : an offici (2004) — Varicella vaccine for susceptible adults: do it today.
How this was built
Per node: a supporting and a mirror PubMed query built from the node's measure / population / comparator / hit_rule; top hits fetched (title + abstract); each record classified (supports / refutes / ambiguous) by xAI with a heuristic fallback; a per-node synthesis is generated strictly from the retrieved PMIDs; the node status is then rolled up to C1–C6. Full query provenance is shown per node above. Reproduce the build: python -m evidence_run. Data: data/evidence_run/state.json.